Inhibiting the compensatory elevation of SLC7A11 protein translation enhances proteasome inhibitor carfilzomib-induced ferroptosis by inhibiting FTH1 and GPX4 expression in B-acute lymphoblastic leukemia
The proteasome inhibitor carfilzomib (CFZ) exerts anti-leukemic activity through multiple mechanisms. Ferroptosis, a nonapoptotic, iron-dependent form of cell death, has emerged as a promising therapeutic strategy for cancer therapy. However, whether CFZ induces ferroptosis in B acute lymphoblastic leukemia (B-ALL) remains unclear. Here, we showed that CFZ markedly induced ferroptosis, as evidenced by increased levels of lipid reactive oxygen species (ROS), Fe²⁺, and malondialdehyde (MDA), along with decreased glutathione (GSH) levels. CFZ induced ferroptosis by reducing ferritin heavy chain (FTH1) and glutathione peroxidase-4 (GPX4) protein levels. However, CFZ induced a rapid compensatory increase in SLC7A11 protein levels. Mechanistically, CFZ reduced polysome fractions and inhibited global translation by inducing phosphorylation of eukaryotic translation initiation factor 2 subunit alpha (p-eIF2α), which is a marker of endoplasmic reticulum stress (ERS). However, CFZ paradoxically enhanced SLC7A11 translation efficiency through a compensatory mechanism. Knockdown of eIF2α attenuated CFZ-induced upregulation of SLC7A11, indicating that CFZ increased SLC7A11 expression by inducing ERS. Pharmacological and genetic inhibition of SLC7A11 further exacerbated CFZ-induced ferroptosis, suggesting that compensatory elevation of SLC7A11 weakened CFZ-induced anti-ferroptotic effects. Notably, CFZ synergized with ferroptosis inducer disulfiram (DSF) to induce ferroptosis. Furthermore, CFZ plus DSF significantly inhibited leukemic cell infiltration and prolonged overall survival (OS) in the BCR-ABL (P190)-driven B-ALL mouse model compared with either agent alone. Finally, CFZ induced ferroptosis in primary B-ALL patient samples. In conclusion, our findings demonstrate that blocking the compensatory SLC7A11 upregulation enhances CFZ-induced ferroptosis. Combined CFZ and DSF therapy represents a promising ferroptosis-based therapeutic strategy for B-ALL patients.
Authors
- Liuzhi Shi (ORCID: https://orcid.org/0000-0001-9484-8616)
- 林清臣
- XiaoFei He
- Xuanyu Yu
- Shirui Yu
- Shixin Zhang
- Qiulin Wu (ORCID: https://orcid.org/0009-0003-0321-491X)
- Chen Xinyao
- Zhou Bin
- Gao Shenmeng
- Wang Hangu
- Zuo Liping
- Chen Haoye
- Zhang Xinyu
- Ye Haige
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-18
- DOI
- https://doi.org/10.5281/zenodo.24344687
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00